| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| J Svartengren, E Pettersson, A Björ. Interaction of the novel antipsychotic drug amperozide and its metabolite FG5620 with central nervous system receptors and monoamine uptake sites: relation to behavioral and clinical effects. Biological psychiatry. vol 42. issue 4. 1997-10-29. PMID:9270901. |
amperozide was very weak or did not interact with several other receptor species including adrenergic, histaminergic, muscarinic, benzodiazepine, gamma-aminobutyric acid, amino acid, opiate, and ca channels; however, amperozide was found to compete for [3h]paroxetine binding for the serotonin transporter in the nanomolar range (ki = 49 nmol/l). |
1997-10-29 |
2023-08-12 |
Not clear |
| C Davidson, J A Stamfor. Chronic paroxetine desensitises 5-HT1D but not 5-HT1B autoreceptors in rat lateral geniculate nucleus. Brain research. vol 760. issue 1-2. 1997-10-28. PMID:9237540. |
the present study examined the effect of chronic paroxetine (10 mg/kg p.o., 21 days) on the 5-ht1b and 5-ht1d autoreceptors controlling 5-ht efflux in slices of rat ventrolateral geniculate nucleus. |
1997-10-28 |
2023-08-12 |
rat |
| C Davidson, J A Stamfor. Chronic paroxetine desensitises 5-HT1D but not 5-HT1B autoreceptors in rat lateral geniculate nucleus. Brain research. vol 760. issue 1-2. 1997-10-28. PMID:9237540. |
peak 5-ht efflux was greater (p < 0.01) after chronic paroxetine (22.2 +/- 1.4 nm, mean +/- s.e.m.) |
1997-10-28 |
2023-08-12 |
rat |
| C Davidson, J A Stamfor. Chronic paroxetine desensitises 5-HT1D but not 5-HT1B autoreceptors in rat lateral geniculate nucleus. Brain research. vol 760. issue 1-2. 1997-10-28. PMID:9237540. |
these data suggest that chronic paroxetine increases evoked 5-ht efflux. |
1997-10-28 |
2023-08-12 |
rat |
| M Di Mascio, E Esposit. The degree of inhibition of dopaminergic neurons in the ventral tegmental area induced by selective serotonin reuptake inhibitors is a function of the density-power-spectrum of the interspike interval. Neuroscience. vol 79. issue 4. 1997-10-23. PMID:9219958. |
electrophysiological techniques and computational methods were used to study the effect of the selective serotonin reuptake inhibitors fluvoxamine, paroxetine and sertraline on the basal activity of dopamine neurons in the ventral tegmental area. |
1997-10-23 |
2023-08-12 |
Not clear |
| M C Swan, A R Najlerahim, J P Bennet. Expression of serotonin transporter mRNA in rat brain: presence in neuronal and non-neuronal cells and effect of paroxetine. Journal of chemical neuroanatomy. vol 13. issue 2. 1997-10-23. PMID:9285352. |
expression of serotonin transporter mrna in rat brain: presence in neuronal and non-neuronal cells and effect of paroxetine. |
1997-10-23 |
2023-08-12 |
rat |
| M C Swan, A R Najlerahim, J P Bennet. Expression of serotonin transporter mRNA in rat brain: presence in neuronal and non-neuronal cells and effect of paroxetine. Journal of chemical neuroanatomy. vol 13. issue 2. 1997-10-23. PMID:9285352. |
the effect of the selective serotonin reuptake inhibitor paroxetine on neuronal expression of the serotonin transporter mrna was examined. |
1997-10-23 |
2023-08-12 |
rat |
| M C Swan, A R Najlerahim, J P Bennet. Expression of serotonin transporter mRNA in rat brain: presence in neuronal and non-neuronal cells and effect of paroxetine. Journal of chemical neuroanatomy. vol 13. issue 2. 1997-10-23. PMID:9285352. |
no significant change (p > 0.1) in serotonin transporter mrna expression was observed following 21 day administration of paroxetine (5 mg/kg per day). |
1997-10-23 |
2023-08-12 |
rat |
| R M Bagby, S H Kennedy, D R Schuller, S E Dickens, C E Minifie, A Levitt, R Joff. Differential pharmacological treatment response in high angry hostile and low angry hostile depressed patients: a retrospective analysis. Journal of affective disorders. vol 45. issue 3. 1997-10-23. PMID:9298429. |
these patients had been treated with either a primarily noradrenergic reuptake inhibitor (desipramine) a ssri (sertraline or paroxetine), or the combined serotonin and norepinephrine reuptake inhibitor (snri), venlafaxine. |
1997-10-23 |
2023-08-12 |
Not clear |
| T R Einarson, A Addis, M Iskedjia. Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder. PharmacoEconomics. vol 12. issue 2 Pt 2. 1997-10-23. PMID:10170453. |
we conducted a cost-effectiveness analysis of acute major depressive disorder (mdd) using serotonin-norepinephrine reuptake inhibitors (snris; venlafaxine), selective serotonin reuptake inhibitors (ssris; fluoxetine, fluvoxamine, sertraline, paroxetine), or tricyclic antidepressants (tcas; amitriptyline, imipramine, desipramine, nortriptyline). |
1997-10-23 |
2023-08-12 |
Not clear |
| J Röschke, P Kögel, R Schlösser, P Wagner, K Mann, W Rossbach, O Benker. Analysis of sleep EEG microstructure in subchronic paroxetine treatment of healthy subjects. Psychopharmacology. vol 132. issue 1. 1997-10-20. PMID:9272758. |
paroxetine is a selective and potent serotonin reuptake inhibitor and its efficacy for the treatment of depression has been proven. |
1997-10-20 |
2023-08-12 |
human |
| J Röschke, P Kögel, R Schlösser, P Wagner, K Mann, W Rossbach, O Benker. Analysis of sleep EEG microstructure in subchronic paroxetine treatment of healthy subjects. Psychopharmacology. vol 132. issue 1. 1997-10-20. PMID:9272758. |
the present study was therefore performed to investigate the impact of subchronic treatment with the selective serotonin reuptake inhibitor paroxetine on the microstructure of the sleep eeg. |
1997-10-20 |
2023-08-12 |
human |
| R J Verkes, D Fekkes, A H Zwinderman, M W Hengeveld, R C Van der Mast, J P Tuyl, A J Kerkhof, G M Van Kempe. Platelet serotonin and [3H]paroxetine binding correlate with recurrence of suicidal behavior. Psychopharmacology. vol 132. issue 1. 1997-10-20. PMID:9272764. |
platelet serotonin and [3h]paroxetine binding correlate with recurrence of suicidal behavior. |
1997-10-20 |
2023-08-12 |
Not clear |
| Q Li, N A Muma, G Battaglia, L D Van de Ka. A desensitization of hypothalamic 5-HT1A receptors by repeated injections of paroxetine: reduction in the levels of G(i) and G(o) proteins and neuroendocrine responses, but not in the density of 5-HT1A receptors. The Journal of pharmacology and experimental therapeutics. vol 282. issue 3. 1997-10-17. PMID:9316875. |
in the present study, we examined the time course effects of another 5-ht uptake inhibitor, paroxetine. |
1997-10-17 |
2023-08-12 |
Not clear |
| N Bal, G Figueras, M T Vilaró, C Suñol, F Artiga. Antidepressant drugs inhibit a glial 5-hydroxytryptamine transporter in rat brain. The European journal of neuroscience. vol 9. issue 8. 1997-10-16. PMID:9283827. |
tissue 5-ht recovery was dose-dependently inhibited by the concurrent perfusion of citalopram, fluoxetine and paroxetine, showing that it essentially measured uptake through the high-affinity 5-ht transporter. |
1997-10-16 |
2023-08-12 |
mouse |
| C A Bennett-Clarke, N L Chiaia, R W Rhoade. Contributions of raphe-cortical and thalamocortical axons to the transient somatotopic pattern of serotonin immunoreactivity in rat cortex. Somatosensory & motor research. vol 14. issue 1. 1997-10-01. PMID:9241726. |
in the first experiment, the specific 5-ht uptake inhibitors, fluoxetine and paroxetine, were administered systemically, animals were killed 3, 6, or 12 h later, and cortices evaluated for 5-ht immunoreactivity. |
1997-10-01 |
2023-08-12 |
rat |
| C A Bennett-Clarke, N L Chiaia, R W Rhoade. Contributions of raphe-cortical and thalamocortical axons to the transient somatotopic pattern of serotonin immunoreactivity in rat cortex. Somatosensory & motor research. vol 14. issue 1. 1997-10-01. PMID:9241726. |
paroxetine treatment caused a reduction in 5-ht immunoreactivity which was maximal 6 h after administration. |
1997-10-01 |
2023-08-12 |
rat |
| E Richelso. Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. Mayo Clinic proceedings. vol 72. issue 9. 1997-10-01. PMID:9294531. |
seven of the newest antidepressants are the serotonin-selective reuptake inhibitors (fluoxetine, sertraline, paroxetine, and fluvoxamine [currently approved in the united states only for obsessive-compulsive disorder]), a serotonin-norepinephrine reuptake inhibitor (venlafaxine), a postsynaptic serotonin antagonist-presynaptic serotonin reuptake inhibitor (nefazodone), and a presynaptic-postsynaptic noradrenergic-serotonergic receptor antagonist (mirtazapine). |
1997-10-01 |
2023-08-12 |
Not clear |
| C Davidson, M Ho, G W Price, B J Jones, J A Stamfor. (+)-WAY 100135, a partial agonist, at native and recombinant 5-HT1B/1D receptors. British journal of pharmacology. vol 121. issue 4. 1997-09-25. PMID:9208142. |
paroxetine (100 nm), the selective 5-ht reuptake inhibitor, increased stimulated 5-ht efflux and reuptake half-life (to 145 +/- 18% and 649 +/- 121%, respectively) on pseudo single pulse stimulations. |
1997-09-25 |
2023-08-12 |
human |
| C Davidson, M Ho, G W Price, B J Jones, J A Stamfor. (+)-WAY 100135, a partial agonist, at native and recombinant 5-HT1B/1D receptors. British journal of pharmacology. vol 121. issue 4. 1997-09-25. PMID:9208142. |
when (+)-way 100135 was added in combination with the uptake blocker, the effect of paroxetine on stimulated 5-ht efflux was potentiated to 282 +/- 48% (p < 0.01) without further effect on the 5-ht reuptake half-life. |
1997-09-25 |
2023-08-12 |
human |